Posted by Michael Wonder on 12 Feb 2021
ICER releases draft evidence report on therapies for multiple myeloma
11 February 2021 - Public comment period now open until March 11, 2021; Requests to make oral comment during public meeting also being accepted.
The Institute for Clinical and Economic Review today released a Draft Evidence Report assessing the comparative clinical effectiveness and value of idecabtagene vicleucel (Bristol-Myers Squibb), ciltacabtagene autoleucel (Johnson & Johnson), and belantamab mafodotin (Blenrep, GlaxoSmithKline) for the treatment of multiple myeloma.
This preliminary draft marks the midpoint of ICER’s eight month process of assessing these treatments, and the findings within this document should not be interpreted to be ICER’s final conclusions.
